Patient-Reported Symptom Score Predicts Outcome in Amyloidosis

Share this content:
Patient-Reported Symptom Score Predicts Outcome in Amyloidosis
Patient-Reported Symptom Score Predicts Outcome in Amyloidosis

MONDAY, Feb. 13, 2017 (HealthDay News) -- A patient-reported symptom score can help predict clinical outcomes in patients with light-chain amyloidosis (AL), according to a study published online Feb. 9 in the American Journal of Hematology.

Rahma Warsame, M.D., from the Mayo Clinic in Rochester, Minn., and colleagues prospectively employed a Hematology Patient Reported Symptom Screen (HPRSS), which included three questions relating to pain, fatigue, and quality of life (QOL), for 302 newly diagnosed patients with AL from 2009 to 2014.

The researchers found that the median overall survival was 53 months, and 102 deaths occurred in the first year. Baseline HPRSS differed significantly for those who lived longer than one year and early-death patients in the domains of fatigue (5 versus 7; P < 0.0001) and QOL (6 versus 5; P = 0.006). Fatigue, QOL, physician-reported performance status, autologous stem cell transplant (ASCT), and Mayo stage were prognostic for survival on univariate analysis. Mayo stage, ASCT, and baseline fatigue remained independently prognostic on multivariate analysis. QOL scores improved significantly over time among the 125 patients with HPRSS measurements at 12 months (6 to 7; P = 0.01).

"Baseline patient-reported fatigue is an independent prognostic factor for survival," the authors write. "Survival at one year was associated with significant improvement in QOL."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »